Showing results (131-140 of 196) with videos related to

Sort By:
Pageof 20
British Journal of Haematology|April 16, 2003
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemiaGordon W Dewald, Stephanie R Brockman, Sarah F Paternoster, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 16, 2021
Vaccination History and Risk of Lymphoma and Its Major SubtypesGeffen Kleinstern, Melissa C Larson, Stephen M Ansell, et al.
Cancer|May 2, 2015
Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomesSameer A Parikh, Jose F Leis, Kari G Chaffee, et al.
Leukemia & Lymphoma|November 26, 2016
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)Tait D Shanafelt, Sameer A Parikh, Peter A Noseworthy, et al.
The American Journal of Surgical Pathology|May 16, 2018
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal RelatednessRong He, Wei Ding, David S Viswanatha, et al.
The Lancet. Haematology|August 30, 2016
Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trialPaolo Strati, Mark Lanasa, Timothy G Call, et al.
Blood|September 11, 2007
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphomaJames R Cerhan, Stephen M Ansell, Zachary S Fredericksen, et al.
British Journal of Haematology|July 16, 2022
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemiaPaul J Hampel, Kari G Rabe, Timothy G Call, et al.
American Journal of Hematology|December 15, 2015
A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)Clive S Zent, Xin Victoria Wang, Rhett P Ketterling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2006
Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disordersAnne J Novak, Deanna M Grote, Steven C Ziesmer, et al.
Pageof 20